One of the structures of the German pharmaceutical company Bayer filed a lawsuit against the drug manufacturer Medisorb from Perm. The court documents indicate that the cause of the dispute was the name, which is protected by a patent.
“The Medisorb company received permission to release a drug with the international non-proprietary name rivaroxaban, which is protected by a patent of the German group. <...> The plaintiff asks the court to oblige the Ministry of Health to cancel the state registration of the drug with the same active substance, and the Perm manufacturer of medicines to stop its production, use and storage, ”is indicated in the file of the Moscow Arbitration Court. A hearing in the case has been scheduled for July 4.
Bayer markets the drug under the brand name Xarelto. The medicine itself is used for deep vein thrombosis and pulmonary embolism. In 2019, the Ministry of Health recommended it for the prevention, diagnosis and treatment of COVID-19. The URA.RU correspondent sent inquiries to the relevant ministry, the Perm company and the Bayer representative office in the Russian Federation. A response is expected.